| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 03/04/2010 | US20100055209 Standardized Extract And Its Use In The Manufacture Of A Medicament |
| 03/04/2010 | US20100055183 Trimeprazine and ethopropazine derivatives for promoting bone growth |
| 03/04/2010 | US20100055124 BRACHYSPIRA PILOSICOLI 72kDa OUTER-MEMBRANE PROTEIN AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF |
| 03/04/2010 | US20100055081 Long-lasting absorption of flavonoids |
| 03/04/2010 | DE102008045339A1 Pharmazeutisches Pellet Pharmaceutical pellet |
| 03/04/2010 | CA2732438A1 Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase |
| 03/04/2010 | CA2724766A1 Use of prebiotic galacto-oligosaccharides in the treatment of intestinal inflammation |
| 03/03/2010 | EP2159224A1 Bromo-phenyl substituted thiazolyl dihydropyrimidines |
| 03/03/2010 | EP2018375B1 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. |
| 03/03/2010 | EP1743648B1 Method for treating inflammation |
| 03/03/2010 | EP1505973B1 Combinations for treating multiple myeloma |
| 03/03/2010 | EP1496920B1 Pharmaceutical composition containing an extract from barleria prionitis linn and its process of preparation |
| 03/03/2010 | EP1386908B1 Amine derivative with potassium channel regulatory function, its preparation and use |
| 03/03/2010 | CN101659639A Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 03/03/2010 | CN101658669A Attenuated live vaccine |
| 03/02/2010 | US7671252 Fad4, Fad5, Fad5-2, and Fad6, novel fatty acid desaturase family members and uses thereof |
| 03/02/2010 | US7671180 Heparin binding protein for use in diagnosis, prvention and treatment of cell proliferative, liver, neurodegeneartive, inflammatory and pancreatic disorders; wound healing agents |
| 03/02/2010 | US7671177 Botulinum neurotoxin type E having increased biological half-life for use treatment and prevention of autonomic, neuromuscular and pain disorders |
| 03/02/2010 | US7671174 appetite stimulants, antiobesity drugs, prolactin production inhibitors; drug screening; G-protein coupled (GPR) |
| 03/02/2010 | US7671090 Inhibitors of α4 mediated cell adhesion |
| 03/02/2010 | US7671087 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| 03/02/2010 | US7671074 Have an affinity for the gabapentin binding site and can be used to treat conditions such as pain, epilepsy, migraine and others; N-{amino-[pyridin-2-yl-methyl)-amino]-methylene}-4-methylbenzenesulfonamide |
| 03/02/2010 | US7670791 regulating an alpha 1G T-type calcium channel in the central nervous system and alpha 1H and alpha 1I T-type calcium channels in the peripheral nervous system; analegesic |
| 03/02/2010 | CA2394615C Substituted 1,3,4-oxadiazoles and a method of reducing tnf-.alpha. levels |
| 03/02/2010 | CA2292836C Prostaglandin pharmaceutical compositions |
| 02/25/2010 | WO2010022381A1 Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
| 02/25/2010 | WO2010021149A1 Spiro compound capable of inhibiting acid secretion |
| 02/25/2010 | WO2010020639A1 Arabinoxylans for modulating the barrier function of the intestinal surface |
| 02/25/2010 | WO2009149795A3 Heterocyclic cyclopropyl-substituted fxr binding compounds |
| 02/25/2010 | WO2009138843A9 Glycosaminoglycan oral use and compositions |
| 02/25/2010 | US20100048702 Prevention of neutrophil recruitment |
| 02/25/2010 | US20100048680 Alpha-1-Antitrypsin Variants and Uses Thereof |
| 02/25/2010 | US20100048651 Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| 02/25/2010 | US20100048648 Thiophene derivatives as S1P1/EDGE1 receptor agonists |
| 02/25/2010 | US20100048639 Oxadiazole derivates as s1p1 receptor agonists |
| 02/25/2010 | US20100048601 HYDROCHLORIDE SALTS OF 8-[-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one AND PREPARATION PROCESS THEREFOR |
| 02/25/2010 | US20100048594 Use of cytohesin inhibitors for chemically inducing longevity |
| 02/25/2010 | US20100048588 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| 02/25/2010 | US20100048565 Benzimidazole derivatives |
| 02/25/2010 | US20100048558 Thienopyridines |
| 02/25/2010 | US20100048520 Rifaximin anti-rectal dysfunction preparation |
| 02/25/2010 | US20100048519 Methods of treatment for ulcerative colitis using aminosalicylate |
| 02/25/2010 | US20100048496 Core 2 GlcNAc-T inhibitors |
| 02/25/2010 | US20100048495 Core 2 GlcNAc-T inhibitors III |
| 02/25/2010 | US20100048493 Method of administering oral flora-improving agent, antibacterial agent and growth promoter |
| 02/25/2010 | US20100048489 Stable Solid Formulation of A GC-C Receptor Agonist Polypeptide Suitable for Oral Administration |
| 02/25/2010 | US20100048488 Immunomodulatory peptides |
| 02/25/2010 | US20100048465 Peptide mimics of melanocyte stimulating hormone |
| 02/25/2010 | US20100048453 Oxazole and thiazole ppar modulator |
| 02/25/2010 | US20100047818 Diagnosis of carcinomas |
| 02/25/2010 | US20100047320 Oral polymeric membrane feruloyl esterase producing bacteria formulation |
| 02/25/2010 | US20100047218 Reversible immortalization |
| 02/25/2010 | US20100047209 Probiotic composition suitable for animals |
| 02/25/2010 | US20100047175 Sincalide Formulations |
| 02/25/2010 | CA2734900A1 Polymorphic form of granisetron hydrochloride and methods of making the same |
| 02/25/2010 | CA2733551A1 Arabinoxylans for modulating the barrier function of the intestinal surface |
| 02/24/2010 | EP2156846A1 Prophylactic or therapeutic agent for diarrhea |
| 02/24/2010 | EP2156824A1 Composition of solifenacin or salt thereof for use in solid formulation |
| 02/24/2010 | EP1465631B1 Pyrimidine a2b selective antagonist compounds, their synthesis and use |
| 02/24/2010 | CN101654479A Mammalian receptor proteins, agents, and methods relating thereto |
| 02/24/2010 | CN100591689C Solid salts of benzazepine compounds and its uses in preparing pharmaceutical compound containing them |
| 02/24/2010 | CN100591332C 7-carboxymethyloxy-3', 4', 5-trimethoxy flavone monohydrate, the preparation method and uses thereof |
| 02/23/2010 | USRE41151 Comprising a modified NSAID, wherein the NSAID is covalently attached either directly or through a linker molecule to a sulfur-containing functional group containing an optionally substituted hydrocarbyl moiety; nonsteroidal anti-inflammatory drugs; side-effect reduction |
| 02/23/2010 | USRE41150 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one |
| 02/23/2010 | US7667053 Cannabinoid-1 (CB1) receptor antagonists and/or inverse agonists; e.g. N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-1,4-benzodioxane-2-carboxamide; psychological disorders, eating disorders |
| 02/23/2010 | US7667040 Azacyclic ethynyl derivatives |
| 02/23/2010 | US7667021 Neutralizing human anti-IGFR antibody |
| 02/23/2010 | US7667013 Gene encoding a guanine nucleotide exchange factor and the gene product thereof |
| 02/23/2010 | US7667008 Heparin binding protein for use in controlling angiogenesis and as wound healing agent |
| 02/23/2010 | US7667002 Peptides and proteins for early liver development and antibodies thereto |
| 02/23/2010 | US7666892 N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}-4-(4-fluorophenoxy)benzenesulfonamide and N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}[1,1'-biphenyl]-4-sulfonamide; chemical intermediates for enzyme inhibitors; especially as inhibitors of MMP12 |
| 02/23/2010 | US7666867 Heteroindanes: a new class of potent cannabimimetic ligands |
| 02/23/2010 | US7666841 for the treatment of diseases and pathological alterations associated with excessive or deregulated TGF- beta 1 expression |
| 02/23/2010 | US7666830 Nutritional composition preventing bacterial overgrowth |
| 02/23/2010 | US7666624 Chemically conjugating a peptide of interest to a heterologous peptide that has been expressed on the coat protein of a cowpea mosaic virus to generate a conjugate and administering the conjugate to a host animal to increase the level of TH1-type immune response |
| 02/23/2010 | US7666422 Methods for the treatment of cancer using anti-CD40 antibodies |
| 02/23/2010 | US7666411 Administering to the subject an effective amount of a substance that binds to IL-13, wherein the substance that binds to IL-13 is an antibody and inhibits IL-13 activation of IL-13R alpha |
| 02/23/2010 | US7666401 Compositions comprising a ligand of Chemerin R |
| 02/23/2010 | CA2520026C High drug load mesalazine sachet |
| 02/23/2010 | CA2433021C Isoindole-imide compounds, compositions, and uses thereof |
| 02/23/2010 | CA2374905C Pyrrolidinyl, piperidinyl or homopiperidinyl-substituted benzopyran derivatives for treating impaired fundic relaxation |
| 02/18/2010 | WO2010019266A2 Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration |
| 02/18/2010 | WO2010019101A1 A crystalline form of 4- (5-{ (ir) -1- [5- (3- chlorophenyl) isoxazol-3-yl] ethoxy } - 4 -methyl- 4h- 1, 2,4- triazol-3-yl) pyridine |
| 02/18/2010 | WO2010019100A1 A new crystalline form of 4- (5- { (ir) -1- [5- (3- chlorophenyl) isoxazol-3-yl] ethoxy } -4-methyl-4h-l, 2, 4- triazol-3-yl) pyridine |
| 02/18/2010 | WO2010018847A1 Recombinant protein-s composition |
| 02/18/2010 | WO2010018837A2 Protein cross-linking inhibitor |
| 02/18/2010 | WO2010018836A2 Polyglutamine aggregation inhibitor |
| 02/18/2010 | WO2010018614A1 Hydrophilic amino acid-containing preparation having improved taste |
| 02/18/2010 | WO2010018329A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof |
| 02/18/2010 | WO2010018328A1 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof |
| 02/18/2010 | WO2010018167A1 Dental formulations for the prevention of dental erosion |
| 02/18/2010 | WO2010017598A1 Anti-il-12/il-23 antibodies |
| 02/18/2010 | US20100041827 Multilayer binding; lamellar surface structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure; organized mobile multifunctional conjugate (OMMC) assembly |
| 02/18/2010 | US20100041826 Multilayer binding; lamellar surface structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure; organized mobile multifunctional conjugate (OMMC) assembly |
| 02/18/2010 | US20100041721 Selective androgen receptor modulators |
| 02/18/2010 | US20100041709 Substituted n-(4-cyano-1h-pyrazol-3-yl)methylamine derivatives, preparation thereof and therapeutic use thereof |
| 02/18/2010 | US20100041708 N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for it's preparation |
| 02/18/2010 | US20100041695 Thieno[2,3-b]pyridines as Potassium Channel Inhibitors |
| 02/18/2010 | US20100041685 Stat3 inhibitors |
| 02/18/2010 | US20100041672 Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome |